Thursday, September 19, 2019 7:21:14 PM
MRC has bothered me since they first appeared on the scene. Something is just not kosher with this firm.
First of all, their website originally claimed they needed to maintain their anonymity. Our own CalMustang exposes the character behind the curtain as Steve Giardino. Their website had to be updated to include his name as President and CEO. I believe this may have been necessary as somebody had to sign MRC's Citizen Petition submitted to the FDA.
Per CalMustang's research, the company was incorporated in New Mexico.
Company headquarters are a mail-drop in a non-descript building in St. Petersburg, FL.
It has been mentioned that Steve Giardino is based in Albany, NY.
There is another principal named James Murphy, that has the title of Marketing Director. His location is listed as Houston, TX.
Seems to be a lot of shenanigans to keep this firm on the 'down-low', yet they have garnered a lot of attention with their $32,000 analytical report and most recently their CP to the FDA bashing the AMRN Reduce-It results.
Just my opinion, but I believe a DS firm, or possibly the whole DS industry could be funding the initial report and the subsequent CP. If you check the MRC website, you will notice that no other bio-pharma firms are investigated. Either this Steve Giardino has an absolutely vicious vendetta against AMRN. or he and MRC have to have backing from other characters.
Attached is the response to MRC's FAQ regarding who is MRC...
Who are the people behind Medical Research Collaborative? *UPDATED*
Currently (as of June 20, 2019) there are two executive members of Medical Research Collaborative, LLC ("MRC"). Neither of these executive members have a medical degree, a PhD, a degree in regulatory science, or a law degree. MRC is a start-up company that is in a state of flux. At any given point in time, there may be multiple members (executive and non-executive) of MRC that have attained the aforementioned degrees, or there may be no members that have attained the aforementioned degrees. It is the intention of MRC to evolve into a research company that has a variety of experts that have earned the aforementioned, established degrees on its staff that serve as members involved in the research of healthcare companies.
The piece, entitled "Identification and Analysis of Amarin Corp.'s Harbingers of Bankruptcy," was wholly constructed by Steven Giardino, the President & CEO of MRC. This piece was professionally proof-read and also reviewed for accuracy/edit suggestions by multiple persons with science backgrounds, one of whom has an advanced medical degree. The final version was/is offered for sale on this website. Although Steven Giardino has self-proclaimed expertise in various pharmaceutical science topics, in regulatory science, and in patent law, he has not earned any of the aforementioned established degrees.
The goal of MRC is to make the research that we produce the focus; we do not believe knowledge of the writer(s) of a work is an appropriate lens through which to judge the work itself, and may bias the reader ("appeal to authority fallacy"). In our view, the work should stand or fall based on its own merits. Furthermore, the subject matter entailing our focus can at times be controversial, and the publication of reports on such result in the provocation of ad hominem attacks from investors in the companies we report on, distracting from the content of the work itself. Also, a truly zealous antagonist that misconstrues he has been harmed by our reports could in some instances jeopardize the careers of prospective/current members of MRC by harassing the establishments at which they are employed (not to mention their family members). For these reasons it is company policy that the identities of the members of MRC, except Steven Giardino, remain anonymous. If another member is named, that name is likely to be a pen name.
Could DS have funded the reports and petitions?? It is certainly plausible. Attached is huge report on omega-3s. It cites over 400 studies and papers.
Conflicts of interest
Financial support for this review was provided by DSM Nutritional Products and Norman Salem, Jr. is employed by DSM, a manufacturer of omega-3 fatty acids.
Here is the full PDF file containing the report and references to the 400+ papers & studies. It is a boatload of info.
https://www.sciencedirect.com/science/article/pii/S0163782715300333
DSM is huge company based in the Netherlands. They are involved in areas other than dietary supplements.
Could a firm such as this, or similar be funding MRC?? I don't know, but it isn't beyond the realm of possibilities.
I think I read in the past month or so that somebody mentioned on the iHub board that private investigators had been employed by AMRN and also a hedge fund to find out more particulars on MRC. I don't know if any of this is true. I certainly would like to find out who is pulling th strings behind MRC.
I have to go now, because the tin-foil in my nicely made hat is digging into my scalp.
Any Sherlock Holmes or Columbos out there?? Please chime in.
Cheers!
Flubber
Recent AMRN News
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM